Wolverine Trading’s DiaMedica Therapeutics DMAC Stock Holding History

Wolverine Trading’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-18,734	Closed	-$71.7K	–	6385
2021 Q2	$89K	Buy	+18,734	New	+$154K	﹤0.01%	5455

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wolverine Trading's DMAC Position: Q3 2021 in Review

Wolverine Trading sold out of DiaMedica Therapeutics (DMAC) in Q3 2021, closing a stake of 18,734 shares — an estimated $71.7K sold.

Wolverine Trading first reported a position in DMAC in Q2 2021 and held it in 1 quarter. The position peaked at $89K in Q2 2021. 34 funds tracked by Wall St. Rank hold DMAC as of Q3 2021.

Wolverine Trading reported no remaining DiaMedica Therapeutics position as of Q3 2021 after selling out during the quarter.
Wolverine Trading sold 18,734 DiaMedica Therapeutics shares in Q3 2021, an estimated $71.7K.
Wolverine Trading first reported a position in DiaMedica Therapeutics in Q2 2021 and held it in 1 quarter.
Wolverine Trading's DiaMedica Therapeutics position peaked at $89K in Q2 2021.
34 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2021.

Based on Wolverine Trading's 13F filing for Q3 2021, filed 12 Nov 2021.